Mitotech

The next name on the list of the largest biotech organizations in Luxembourg is Mitotech. It is a biotech company with a portfolio of novel mitochondria-targeted small molecules. Since its establishment in 2009 in Luxembourg, this company has renovated its lead compound SkQ1 for the treatment of dry eye disease in a condition where tears are unable to bring enough lubrication to the eyes. Additionally, this clinical-stage company aims to target the mitochondria to tackle neurodegenerative and metabolic disorders.

Over the years, Mitotech has witnessed the process of clinical trials for SkQ1. A phase 3 study conducted in the U.S. proved the candidate’s efficacy in decreasing the symptoms of dry eye disease in participants. In addition, the compound is also being evaluated in preclinical studies for the treatment of glaucoma, Leber’s hereditary optic neuropathy (LHON), dry age-related macular degeneration (AMD), and uveitis.

With a view to making use of the important breakthrough in delivering highly active compounds into mitochondria across a wide spectrum of neurodegenerative and metabolic indications, Mitotech promises to provide medicines based on this novel mechanism of action to patients worldwide. Simultaneously, Mitotech also aims to find out solutions to this underserved area of drug development with novel small molecules designed to target mitochondrial oxidative stress and mitochondrial lipid peroxidation.

Founded: 2009
Headquarters: Luxembourg City, Luxembourg
Website: https://www.mitotechpharma.com/